Solara Active Pharma reported a 55% rise in June quarter profit to ₹16.3 crore, supported by a 19.7% revenue growth. However, margins were pressured by rising input costs and losses in its Ibuprofen business, leading the company to delay plans for carving out its CRAMS and polymer divisions.
Detailed Coverage
Solara Active Pharma Sciences reported a consolidated net profit of ₹16.3 crore for the quarter ended June 30, 2026, marking a 55% increase compared to ₹10.5 crore in the same period last year. The company’s revenue from operations grew 19.7% to ₹382 crore, up from ₹319 crore in the year-ago quarter. Following the result announcement, the stock climbed 5% on the National Stock Exchange.
Margin Pressure and Ibuprofen Drag
While the bottom line improved, operational profitability faced challenges. EBITDA for the quarter rose by 10% to ₹62.6 crore; however, the EBITDA margin contracted to 16.4% from 17.8% in the previous year. Management attributed this margin squeeze to higher input costs, partially linked to geopolitical issues in West Asia affecting supply chains. A significant factor impacting overall profitability remains the commodity Ibuprofen business, which continues to report low gross margins and negative EBITDA. The company has engaged bankers to evaluate strategic options for this division, with a decision expected by the end of the second quarter of fiscal year 2027.
Strategic Shifts and Business Focus
Due to the ongoing uncertainty surrounding the Ibuprofen segment, Solara has decided to defer the proposed carve-out of its polymers and Contract Research and Manufacturing Services (CRAMS) businesses. These restructuring plans are now on hold until a resolution for the Ibuprofen unit is reached. Despite these pressures, the company’s Base Business showed steady performance, with a 24% revenue increase to ₹307.7 crore and EBITDA of ₹72.2 crore, signaling growth in its core pharmaceutical operations.
Balance Sheet Improvements
Solara Active Pharma also focused on reducing its financial obligations during the quarter. The company lowered its net debt by ₹134.6 crore, bringing the total net debt down to ₹479.5 crore. This debt reduction has brought the annualized net debt-to-EBITDA ratio to approximately 1.9 times. Moving forward, investors may track the progress of the strategic decision regarding the Ibuprofen business and its potential impact on the company’s margin profile and future restructuring plans.